| Factor Information | |
|---|---|
| Data ID | 310 |
| Factor | t-PA(tissue-type plasminogen activator) |
| Description | one of microvascular dysfunction markers |
| Biomarker | YES |
| Classification | E2 (physiological factor - biochemical index) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | PAH-CHD patients |
| p Value | 0.009 |
| Conclusion | Compared to controls, patients had elevated baseline tissue-type plasminogen activator. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 101 |
| CHD Type | isolated CHD |
| CHD Subtype | CHD with PAH |
| Reference | |
|---|---|
| PMID | 30343508 |
| Year | 2019 |
| Title | Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease. |
| Sample | ||
|---|---|---|
| Population | Adolescents and adults | |
| Source | blood | |
| Region | Brazil, Sao Paulo | |
| Method | Student’s t test or the Mann- Whitney test | |
| Race | American | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | N/A(Treatment) | N/A(Control) |
| Number | 31 | N/A |
| Age | 10-54 years | 18-50 years |
| Gender (Male: Female) | 10:21 | N/A |
| Marker Level | N/A | N/A |
